What is the proper protocol for using technetium‑99m sestamibi (Cardiolite) in myocardial perfusion imaging, including dosing, patient preparation, and contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Technetium-99m Sestamibi (Cardiolite) Protocol for Myocardial Perfusion Imaging

Cardiolite should be injected 1 minute before the end of exercise stress, with imaging acquired 15-60 minutes post-stress for optimal detection of coronary artery disease. 1

Dosing Protocol

Use a rest/stress protocol with low-dose rest (185-296 MBq or ~7 mCi) followed by high-dose stress (555-925 MBq or ~25 mCi) with a 2-4 hour interval between injections. 2, 3 This sequence is superior to stress/rest protocols because:

  • The rest image represents a "true" baseline without residual stress activity 3
  • Better image contrast between abnormal and normal zones on exercise images 2
  • Superior ability to detect reversibility of perfusion defects 2
  • The typical effective dose range for a 1-day rest-stress protocol is 9.8-16.3 mSv 4

Rapid Protocol Option

For improved patient throughput, a rapid same-day protocol can be completed in approximately 108 minutes total examination time 5, 6:

  • Inject low-dose at rest (256 MBq)
  • Acquire rest images immediately
  • Have patient drink 400 mL water to clear subdiaphragmatic activity
  • Perform stress test immediately after rest imaging
  • Inject high-dose at stress (1312 MBq)
  • Patient drinks another 400 mL water
  • Acquire stress images 60 minutes post-injection

Injection Timing

Critical timing considerations:

  • Exercise stress: Inject 1 minute before end of exercise 1
  • Pharmacological stress: Inject 1-2 minutes before end of vasodilator infusion 7
  • This timing is essential because Tc-99m sestamibi does not redistribute after injection 1

Image Acquisition

Acquire images 15-60 minutes after injection 1, though evidence suggests:

  • Early imaging (15 minutes or even 6-8 minutes) may be more sensitive for detecting ischemia due to some degree of tracer redistribution 8, 9
  • Images can be obtained up to 4 hours post-injection due to lack of significant redistribution 1
  • SPECT imaging using 180-degree anterior arc is standard 2
  • Display as tomographic slices in 3 axes: short axis, vertical long axis, horizontal long axis 1

Patient Preparation

Pre-imaging requirements:

  • Fasting status: Follow standard stress test preparation
  • Medications: Coordinate with referring physician regarding beta-blockers, calcium channel blockers, nitrates
  • Hydration strategy: Have patient drink 400 mL water after each injection to reduce subdiaphragmatic tracer activity and improve image quality 5, 6

Stress modality selection:

  • Exercise stress preferred when patient can achieve adequate workload 1
  • Pharmacological stress (adenosine, regadenoson, or dobutamine) for patients unable to exercise due to deconditioning, peripheral vascular disease, orthopedic disabilities, neurological disease 1, 7

Contraindications

Based on the FDA label 10 and clinical guidelines, there are no absolute contraindications to Cardiolite itself, but contraindications relate to the stress testing component:

Exercise stress contraindications:

  • Acute myocardial infarction (within 2 days)
  • Unstable angina not stabilized
  • Uncontrolled cardiac arrhythmias
  • Severe symptomatic aortic stenosis
  • Acute pulmonary embolism or infarction
  • Acute myocarditis or pericarditis

Vasodilator stress contraindications:

  • Bronchospastic lung disease for adenosine/regadenoson
  • High-grade AV block without pacemaker
  • Severe hypotension

Key Advantages of Tc-99m Sestamibi

Sestamibi offers several advantages over thallium-201 1:

  • Shorter half-life (6 hours vs 73 hours) enabling higher isotope doses
  • Higher photon energy resulting in improved image quality with greater resolution and less attenuation
  • Lower radiation dose to patient 4, 11
  • Flexible imaging window (up to 4 hours post-injection)
  • Can be used with ECG-gating for simultaneous assessment of perfusion and function

Common Pitfalls to Avoid

Critical protocol errors:

  • Avoid stress/rest sequence with short intervals - leads to underestimation of ischemia (7.4% of segments misclassified as scar rather than ischemia) 3
  • Don't delay imaging beyond 60 minutes routinely - while possible, early imaging may capture more ischemia 8, 9
  • Inadequate dose ratio - maintain at least 1:3 rest-to-stress ratio, preferably 1:5, to overcome residual rest activity 5
  • Inferior wall artifacts - more common in patients <70 years old; water drinking helps but doesn't eliminate all artifacts 6

Image Interpretation

Perfusion pattern interpretation:

  • Reversible defect (present on stress, absent at rest) = myocardial ischemia indicating significant coronary stenosis 1, 12
  • Fixed defect (present on both stress and rest) = prior myocardial infarction with loss of viable myocardium 1, 12
  • Homogeneous uptake = normal myocardium and perfusion, absence of clinically significant disease 12

The diagnostic accuracy using proper protocols shows sensitivity of 84-95% and specificity of 63-97% for detecting coronary artery stenosis >50% 5, 6, 13.

References

Research

Comparison of same-day protocols using technetium-99m-sestamibi myocardial imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992

Research

Feasibility of a rapid protocol of 1-day single-isotope rest/adenosine stress Tc-99m sestamibi ECG-gated myocardial perfusion imaging.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2008

Guideline

myocardial perfusion scintigraphy: the evidence.

European Journal of Nuclear Medicine and Molecular Imaging, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.